“A one-on one-off approach to future medicines funding is a slippery slope to a NZ Pharmac for Australia, that cannot be allowed to happen," said Better Access Australia chair Felicity McNeill PSM.
'HTA review will achieve savings, but it won’t achieve better access for all'
September 12, 2024 Latest NewsBioPharmaNews of the DayLatest Video
New Stories
-
Wesfarmers Health announces plan to build new fulfilment centre in Cairns
September 17, 2024 - - Latest News -
Medicines Australia launches next phase of campaign in PM's electorate
September 17, 2024 - - Latest News -
The HTA Review report - 'Red Flag' number three of five
September 17, 2024 - - Latest News -
Immutep says its candidate in combination with Keytruda delivered positive efficacy and safety profile
September 16, 2024 - - Latest News -
Medicines Australia responds to questions on the HTA Review
September 16, 2024 - - Latest News -
The HTA Review report - 'Red Flag' number two of five
September 16, 2024 - - Latest News -
Australian company Kazia executes licensing agreement with QIMR Berghofer
September 16, 2024 - - Latest News